The epidemic situation of pulmonary tuberculosis in China is challenging. Pathogenic test of Mycobacterium tuberculosis is the “golden indicator” for the diagnosis of pulmonary tuberculosis, but the activity judgment becomes difficult when the etiological examination is negative. In addition, evaluation of activity of pulmonary tuberculosis post-treatment also encounters the pathogenic problem. This expert consensus introduces the current evaluation methods for activity judgment of pulmonary tuberculosis, and sets standards of clinical comprehensive evaluation of activity. Meanwhile, it points out the existing problems of activity judgment and its clinical implementation and discusses its future development.
Authors made analysis on the similarities and differences of Chinese Guidelines on chemotherapy of drug-resistant tuberculosis (2019) (abbreviated as “Guidelines 2019”) and Chinese consensus on multidrug-resistant tuberculosis and rifampin resistant tuberculosis treatment (2019 edition) and compared with WHO guidelines, provided the ideas from the elaboration on drug groups divided, implement approach of anti-TB treatment,the characteristics of Guidelines 2019 and future development direction of national drug-resistant treatment for clinical physicians.
Drug-resistant tuberculosis (TB) has the characteristics of long treatment course, regimens with variety of drugs,high incidence rate of drug side-effect, how to treat drug side-effect correctly is one of essential factors of improving the outcome of drug-resistant tuberculosis. This expert consensus will elaborate in the treatment of side-effects from each drug and each system,treatment monitoring for drug side-effect and will provide the normative methods and principles for side-effects of drugs.
Drug-resistant tuberculosis is a difficult problem in the field of TB treatment.Spinal tuberculosis is a common extrapulmonary secondary tuberculosis. Drug resistance seriously affects the therapeutic effect and prognosis of spinal tuberculosis.This expert consensus provides a brief introduction to the definition and epidemiology of drug-resistant spinal tuberculosis, proposes the diagnostic criteria and methods of drug-resistant spinal tuberculosis, puts forward some suggestions on the formulation of anti-tuberculosis treatment, the choice of surgical timing and surgical methods, prospects the research development of drug-resistant spinal tuberculosis in the future.
Drug-resistant tuberculosis (DR-TB) especially multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) are one of the most difficult problems to be solved in clinical practice. Anti-tuberculous drug susceptibility tests (DST) provide experimental basis for the diagnosis of DR-TB. This expert consensus briefly introduces the common M.tuberculosis (MTB) DST methods (including phenotypic DST and molecular DST) used in clinic, proposes the strategies of MTB drug resistance detection and correct interpretation of the results, points out the problems of DST detection technology and clinical application, and prospects the development of DST in the future.
School students in crowed environment are susceptible to tuberculosis(TB), often resulting outbreaks and public health emergencies. We give further advices on the investigation of index cases and their close contacts, diagnosis and treatment of active TB patients and latent TB infection and their standardized management, aiming at facilitating TB epidemiology investigation, scene disposal and related effect evaluation.
To interpret the “Treatment of Drug-resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline (ATS Guideline)”, including the drugs, formulating treatment regimen and duration, as well as treatment of isoniazid-resistant TB, preventive therapy of close contacts of MDR-TB; and then to compared “ATS Guideline” with “Guideline for Chemotherapy of Drug Resistant Tuberculosis (2019)” in China.
This standard stipulates the principles, institutional requirements, inspection items, service modes, data management and utilization requirements for carrying out the health check-up for rural residents. It is applicable to the standardized management of the health check-up for rural residents aged 15 years old and above under the relevant national laws and regulations.
The global incidence of tuberculosis has declined marginally from 2000 to 2017, but it is still under poor control in parts of Africa and Asia. Multidrug-resistant tuberculosis (MDR-TB) has become a major concerned issue in the global public health system, and the optimum medications and treatment regimens for MDR-TB remain controversial. This review summarizes the treatment guidelines for MDR-TB in recent years and analyzes the background, specific recommendations, implementations and trends of these guidelines.
BCG vaccine is of great significance in preventing tuberculosis.China adopts the strategy of vaccinating newborns with BCG vaccine at birth.In this paper, the author discussed the quality control standards of BCG vaccine of domestic and foreign, the general situation of BCG vaccine strains in China, the induced immune response and adverse reactions of BCG vaccine in China, so as to provide basic information for understanding BCG vaccines in China.
In order to meet the needs of the current tuberculosis prevention and control work in China,the National Health and Family Planning Commission (NHFPC) released the health industry standard for the Classification of tuberculosis (WS 196-2017) on November 9, 2017. The new classification standards are based on the etiology, epidemiological characteristics, clinical manifestations, laboratory tests and differential diagnosis of tuberculosis. Amendments mainly focus on active TB, and it is in line with the characteristics of the change and development of tuberculosis. The trachea and bronchial tuberculosis and tuberculous pleurisy are incorporated into pulmonary tuberculosis. And the molecular and bacteriological examination result are defined as pathogenic examination. At the same time, the results of drug susceptibility test are included in the active tuberculosis classification. This standard also cover Mycobacterium tuberculosis latent infection and inactive pulmonary tuberculosis. The clear definition of the two groups are more conducive to the key prevention and control of tuberculosis. Increasing the drug resistance classification is beneficial to understand the status of drug-resistant tuberculosis and to evaluate the epidemic status of drug-resistant tuberculosis scientifically and objectively. The Classification of tuberculosis (WS 196-2017) will provide a strong technical support for the realization of the goal of ending tuberculosis prevention and control in China in 2035.
The diagnosis of tuberculous pleurisy is difficult due to the low positive rate of etiology in pleural effusion and atypical clinical symptoms. The new health industry standards criteria(WS 288-2017) issued for tuberculous pleurisy will be helpful to diagnose systematically in practice. This paper focused on interpretation of tuberculous pleurisy from the new national standards for readers to understand it better.
Clinical diagnosed pulmonary tuberculosis (TB), known as TB cases without pathogenic evidence. Because of lacking typical clinical symptoms, misdiagnosis is not rare in clinical practice. The newly released national standard on Diagnosis for pulmonary tuberculosis (WS 288-2017) sets up a new criteria for clinical diagnosed TB case with consideration of current new diagnostic tools. This paper aims to interpret the new national standard on clinical diagnosed TB case, and provide guidance to clinicians’ routine practice.
On November 9, 2017, the National Health and Family Planning Commission of the People’s Republic of China issued a new health standard for the Classification of tuberculosis (WS 196-2017), which will be formally implemented on May 1, 2018. By the introduction of tracheobronchial tuberculosis incidence, clinical features, diagnosis, classification and treatment methods in WS 196-2017 standard, this paper focuses on the clinical diagnosis of tracheobronchial tuberculosis and especially provides a feasible reference for the key roles of bronchoscopy in the diagnosis and interventional treatment of tracheobronchial tuberculosis.